Search Results

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (“Aires” or the “Company”), a pioneer in innovative technology designed to safeguard against electromagnetic radiation and enhance human well-being, issues this news release in order to clarify certain financial disclosure contained in its news release dated June 18, 2024 (the “June 18th Press Release”).

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to like to clarify its press release of October 3, 2023.

The U.S. Food and Drug Administration issued final guidance to provide the medical device industry clarity on the definition of “remanufacturing” for reusable devices needing maintenance or repair.

Amid recent backlash stemming from market withdrawals and trial delays, the FDA seeks to further clarify its requirements for confirmatory trials for therapies seeking the shortened path to market.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce it has commenced its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)[1], with the initiation of the first clinical site at the Urology Cancer Center / XCancer Omaha, NE.

The U.S. Food and Drug Administration took important steps to advance the FDA’s regulatory process for intentional genomic alterations in animals.

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) wishes to clarify certain disclosure in its management information circular (the “Circular”)

For the third time this year, Clarify Health, a leading healthcare analytics platform company, is being honored by Frost & Sullivan.